New drugs in gynecologic cancer

Current Treatment Options in Oncology

Volumn 2, Issue 2, 2001, Pages 119-128

  Daud, Adil ^a   Munster, Pamela ^a   Spriggs, David R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CDDP; Epothilone; Oxaliplatin; Paclitaxel; Ubiquitin Proteasome System

Indexed keywords

AMINOPYRIDINE DERIVATIVE; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM(II); AMMINEDICHLORO(2-METHYLPYRIDINE)PLATINUM(II); ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BBR 3464; BORONIC ACID DERIVATIVE; BORTEZOMIB; CISPLATIN; DRUG DERIVATIVE; GEFITINIB; HYDROXAMIC ACID; MACROCYCLIC LACTAM; MONOCLONAL ANTIBODY; PACLITAXEL; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE; PYRAZINE DERIVATIVE; PYROXAMIDE; QUINAZOLINE DERIVATIVE; TRASTUZUMAB;

DRUG ANTAGONISM; FEMALE; FEMALE GENITAL TRACT TUMOR; HUMAN; REVIEW;

AMINOPYRIDINES; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CISPLATIN; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; HYDROXAMIC ACIDS; LACTAMS, MACROCYCLIC; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PROTEIN-TYROSINE KINASES; PYRAZINES; QUINAZOLINES;

EID: 0035323027     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-001-0054-0     Document Type: Article

References (33)

1. Fink D, N∄bel S, Aebi S, et al.: The role of mismatch repair in acquired platinum drug resistance. Cancer Res 1996, 56:4881–4886.
2. Vaisman A, Varechenco M, Umar A, et al.: The role of hMLH1, hMSH3 and hMSH6 defects in cisplatin and oxalipatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998, 58:3579–3585.
3. Sessa C, ten Bokkel Huinink WW, du Bois A:Oxaliplatin in ovarian cancer. Ann Oncol 1999, 10(suppl):S55-S57. DOI: 10.1023/A:1008311502493
4. Piccart MJ, Green JA, Lacave AJ, et al.: Oxaliplatin or paclitaxel in patients with platinum pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000, 18:1193–1202.
5. Holford J, Sharp SY, Murrer BA, et al.: In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998, 77:366–373.
6. Raynaud FI, Boxall FE, Goddard PM, et al.: Cis Amminedichloro(2methylpyridine) Platinum (II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology and pharmacokinetics in mice. Clin Cancer Res 1997, 3:2063–2074.
7. Trigo JM, Beale P, Judson IR, et al.: Phase I and pharmacokinetic study of cis diamminedichloro(2-methylpyridine) platinum II (ZD0473), a novel sterically hindered platinum complex in patients with advanced solid malignancies. ASCO 1999, abstract 648.
8. Manzotti C, Pratesi G, Menta E, et al.: BBR 3464— a novel triplatinum complex exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin Cancer Res 2000, 6:2626–2634.
9. Sharp SY, Kelland LR: BBR-3464. Current Opinion in Oncologic, Endocrine and Metabolic Investigational Drugs 2000, 2:353–360.
10. Pratesi G, Perego P, Polizzi D, et al.: A novel charged trinuclear platinum complex effective against cisplatin resistant tumors: hypersensitivity of p53 mutant human tumors xenografts. Br J Cancer 1999, 80:1912–1919. DOI: 10.1038/sj.bjc.6690620
11. Kowalski RJ, Giannakakou P, Hamel E: Activities of the microtubulin stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (taxol). J Biol Chem 1997, 272:2534–2541. DOI: 10.1074/jbc.272.4.2534
12. Chou TC, Zhang XG, Balog A, et al.: Desoxyepothilone B: an efficacious microtubule targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci U S A 1998, 95:9642–9647. DOI: 10.1073/pnas.95.16.9642
13. Calvert PM, O’Neill V, Azzabi A, et al.: A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumors. 11th Annual NCI-EORTC-AACR Symposium, 2000. Abstract 257.
14. Warrell R, He LZ, Richon V, et al.: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998, 90:1621–1625. DOI: 10.1093/jnci/90.21.1621
15. Cameron E, Bachman KE, Myohanen S, et al.: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999, 21:103–107. DOI: 10.1038/5047
16. Ciechanover A: The ubiquitin-proteasome pathway: on protein death and cell life. Embo J 1998, 17:7151–7160. DOI: 10.1093/emboj/17.24.7151
17. Hershko A, Ciechanover A: The ubiquitin system. Annu Rev Biochem 1998, 67:425–479. DOI: 10.1146/annurev.biochem.67.1.425
18. Adams J, Palombella VJ, Elliott PJ: Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000, 18:109–121. DOI: 10.1023/A:1006321828515
19. Teicher BA, Ara G, Herbst R, et al.: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999, 5:2638–2645.
20. Glas R, Bogyo M, McMaster JS, et al.: A proteolytic system that compensates for loss of proteasome function. Nature 1998, 392:618–622. DOI: 10.1038/33443
21. Drexler HC: Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 1997, 94:855–860. DOI: 10.1073/pnas.94.3.855
22. Uehara Y, Hori M, Takeuchi T, Umezawa H: Screening of agents which convert“transformed” morphology of RSV infected kidney cells“normal” cells: identification of active agent as herbimycin and its inhibition of src kinase. Jpn J Cancer Res 1985, 76:672–675.
23. Stebbins CE, Russo AA, Schnieder C, et al.: Crystal structure of an Hsp90-geldaamycin complex; targeting of a protein chaperone by an antitumor agent. Cell 1997, 89:239–250. DOI: 10.1016/S0092-8674(00)80203-2
24. Schnur RC, Corman ML, Gallaschun RJ, et al.: Inhibition of the oncogen product p185erB-2 in vitro and in vivo by geldanamycin and derivatives. J Med Chem 1995, 38:3806–3812. DOI: 10.1021/jm00019a010
25. Schulte TW, Blagosklonny MV, Ingui C, Neckers L:Disruption of the Raf-1 Hsp90 molecular complex results in destabilization of Raf1 and loss of Raf-1 Ras association. J Biol Chem 1995, 270:24585–24588. DOI: 10.1074/jbc.270.41.24585
26. Srethpakdi M, Liu F, Tavorath R, Rosen N: Inhibition of Hsp90 function causes Rb dependent G1 arrest. Cancer Res 2000, 60:3940–3946.
27. Münster PN, Srethapakdi M, Moasser MM, Rosen N: Inhibition of Hsp90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res, In press.
28. Al-Obeidi FA, Lam KS: Development of inhibitors for protein kinases. Oncogene 2000, 19:5690–5701. DOI: 10.1038/sj.onc.1203926
29. Stebbing J, Copson E, O’Reilly S: Herceptin (transuzamab) in advanced breast cancer. Cancer Treat Rev 2000, 26:287–290. DOI: 10.1053/ctrv.2000.0182
30. Mendelsohn J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997, 12:2703–2707.
31. Baselga J, Pfister D, Cooper MR, et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000, 18:904–914.
32. Sirotnak FM, Zakowski MF, Miller VA, et al.: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000, 67:4885–4892.
33. Baselga J, Averbusch SD: ZD1839 (‘Iressa’) as an anticancer agent. Drugs 2000, 60(suppl):33–40. DOI: 10.2165/00003495-200060001-00004